Skip to main content
. 2020 Oct 13;9:e57191. doi: 10.7554/eLife.57191

Figure 2. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in lipid fraction) for variants in gene regions representing targets of lipid-lowering treatments.

Estimates are scaled to a one standard deviation increase in LDL-cholesterol for the HMGCR, PCSK9, LDLR, and NPC1L1 regions, and a one standard deviation increase in triglycerides for the APOC3 and LPL regions. A: associations with overall cancer for each gene region in turn. B: associations with site-specific cancers for variants in the HMGCR gene region.

Figure 2.

Figure 2—figure supplement 1. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in LDL-cholesterol) for variants in the PCSK9 gene region.

Figure 2—figure supplement 1.

Figure 2—figure supplement 2. Gene-specific Mendelian randomization estimates (odds ratio with95%confidence interval per one standard deviation increase in LDL-cholesterol) for variants in theLDLRgene region.

Figure 2—figure supplement 2.

Figure 2—figure supplement 3. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in LDL-cholesterol) for variants in theNPC1L1gene region.

Figure 2—figure supplement 3.

Figure 2—figure supplement 4. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in LDL-cholesterol) for variants in theAPOC3gene region.

Figure 2—figure supplement 4.

Figure 2—figure supplement 5. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in LDL-cholesterol) for variants in theLPLgene region.

Figure 2—figure supplement 5.

Figure 2—figure supplement 6. Genetic associations with LDL-cholesterol (standard deviation units) plotted against genetic associations with overall cancer (log odds ratios) for six variants in the HMGCR gene region.

Figure 2—figure supplement 6.

Figure 2—figure supplement 7. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in LDL-cholesterol) for variants in the HMGCR gene region excluding self-reported outcomes.

Figure 2—figure supplement 7.

Figure 2—figure supplement 8. Gene-specific Mendelian randomization estimates (odds ratio with 95% confidence interval per one standard deviation increase in LDL-cholesterol) for variants in the HMGCR gene region excluding those with a cancer diagnosis other than site-specific cancer under analysis.

Figure 2—figure supplement 8.